1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2022, Issue 1
  5. Article
Volume 2022, Issue 1
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Immune-mediated necrotizing myopathy (IMNM) or necrotizing autoimmune myopathy includes a set of distinct disorders associated with marked myasthenia, myofiber necrosis, and high creatine kinase levels. Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) and anti-signal recognition particle (anti-SRP) are the two main autoantibodies associated with IMNM. Anti-HMGCR is usually associated with statin use. However, it may also be discovered in children without previous statin exposure, suggesting the existence of a complex genetic–environmental relationship in disease pathogenesis. Anti-SRP IMNM tends to present with more severe disease distinguished by pronounced myasthenia, worse neurologic outcomes, and treatment refractoriness. Its pathogenesis is also unknown; however, preliminary data suggest an antibody–complement-mediated mechanism of muscle cell lysis. Herein, we present the case of a 63-year-old man diagnosed with anti-HMGCR- and anti-SRP-positive IMNM that was treated with multiple immunosuppressants resulting in clinical improvement.

© 2022 Khan, Kazmi, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.6
2022-02-22
2024-10-03
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2022/1/qmj.2022.6.html?itemId=/content/journals/10.5339/qmj.2022.6&mimeType=html&fmt=ahah

References

  1. Upreti S, Fayyaz B, Bongu RP: Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report. J Community Hosp Intern Med Perspect. 2019, 9:33-35. 10.1080/20009666.2019.1571882.
     [Google Scholar]
  2. Greenberg, SA: Pathogenesis of inflammatory myopathies. UpToDate. Targoff IN, Shefner JM, Ramirez-Curtis M (ed): UpToDate, Waltham, MA; 2021.
     [Google Scholar]
  3. Ladislau L, Arouche-Delaperche L, Allenbach Y, Benveniste O: Potential pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-coa reductase antibodies in immune-mediated necrotizing myopathies. Curr Rheumatol Rep. 2018, 20:56. 10.1007/s11926-018-0763-z.
     [Google Scholar]
  4. Villa L, Lerario A, Calloni S, Peverelli L, Matinato C, DE LISO FE, et al.: Immune-mediated necrotizing myopathy due to statins exposure. Acta Myol. 2018, 37:257-262.
     [Google Scholar]
  5. Mohassel P, Mammen AL: Anti-HMGCR myopathy. J Neuromuscul Dis. 2018, 5:11-20. 10.3233/JND-170282.
     [Google Scholar]
  6. Khan MH, Patel A, Pendharkar S: Anti-signal recognition particle necrotizing autoimmune myopathy: an atypical presentation. Cureus. 2018, 10:e3766. 10.7759/cureus.3766.
     [Google Scholar]
  7. Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayam K, et al.: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016, 87:1038-1044. 10.1136/jnnp-2016-313166.
     [Google Scholar]
  8. Rojana-udomsart A, Mitrpant C, Bundell C, Price L, Luo YB, Fabian V, et al.: Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM). J Neuroimmunol. 2013, 264:65-70. 10.1016/j.jneuroim.2013.08.008.
     [Google Scholar]
  9. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, et al.: Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011, 63:1961-1971. 10.1002/art.30344.
     [Google Scholar]
  10. Kalinova D, Kopchev A, Kolarov Z, Rashkov R: Immune-mediated necrotizing myopathy with anti-SRP autoantibodies and typical clinical presentation. Clin Med Rev Case Rep. 2020, 7:314. 10.23937/2378-3656/1410314.
     [Google Scholar]
/content/journals/10.5339/qmj.2022.6
Loading
  • Article Type: Case Report
Keyword(s): Anti-HMGCR, anti-SRP, immune-mediated necrotizing myopathy, rheumatology and statin use

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error